Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Clearmind Medicine Inc
(NQ:
CMND
)
1.310
-0.010 (-0.76%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Clearmind Medicine Inc
< Previous
1
2
3
4
Next >
Clearmind Medicine Inc.’s Psychedelic-Based Therapeutics Are Revolutionary To The Pharmaceutical Sector; Treating AUD In The Crosshairs ($CMND)
January 03, 2023
Via
AB Newswire
Topics
Intellectual Property
Exposures
Intellectual Property
Clearmind Medicine Inc. Positions To Deliver A First-To-Market Psychedelic-Based Treatment For AUD ($CMND)
December 29, 2022
Via
AB Newswire
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Clearmind Medicine Announces Shareholders Meeting Results
December 29, 2022
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Israel-Based Clearmind Medicine Announces First Clinical Center to Join Its Clinical Trial for Alcohol Use Disorder
December 28, 2022
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Inc. Scores Milestone Patent Issuance To Expedite And Protect Psychedelic-Based Treatment For AUD ($CMND)
December 27, 2022
Via
AB Newswire
Topics
Intellectual Property
Exposures
Intellectual Property
In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews Clearmind Medicine Inc's CEO, Dr. Adi Zuloff-Shani
December 22, 2022
Via
ACCESSWIRE
Israel- Based Clearmind Medicine Granted U.S. Patent for Psychedelic-Based Alcohol Substitute
December 21, 2022
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Inc. Is Disrupting The Pharmaceuticals Landscape; First-To-Market Psychedelic-Based Treatment For AUD In Its Crosshairs ($CMND)
December 21, 2022
Via
AB Newswire
Israeli Based Biotech Company Clearmind Medicine Inc’s CEO, Dr. Adi Zuloff-Shani, Issues Letter to Shareholders
December 15, 2022
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Israeli Based Biotech Company Clearmind Completes IND-Enabling Studies for CMND-100
December 13, 2022
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Israeli Biotech Clearmind Medicine Appoints ex-Red Bull Executive Special Advisor for Developing MEAI as Alcohol Substitute
December 09, 2022
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Announces Initiation of CMND-100 Manufacturing Program to Address its Upcoming Clinical Trial
November 23, 2022
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Aegis Capital Corp. Acted as Sole Bookrunner on a $7.5 Million Underwritten Public Offering & Uplisting for Clearmind Medicine Inc. (NASDAQ: CMND)
November 17, 2022
Via
ACCESSWIRE
Clearmind Medicine Announces Closing of US$7.5 Million Public Offering and Uplisting to the Nasdaq Capital Market
November 17, 2022
From
Clearmind Medicine Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.